Company: ABUS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001447028-25-000083
Chunk: 3

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 3
---
97,366 106,018 Total liabilities and stockholders' equity$131,707 $144,401 

See accompanying notes to the consolidated financial statements.

 77

ARBUTUS BIOPHARMA CORPORATION

Consolidated Statements of Operations and Comprehensive Loss

(Expressed in thousands of US Dollars, except share and per share amounts)

 Year ended December 31, 20242023RevenueCollaborations and licenses$3,919 $14,274 Non-cash royalty revenue2,252 3,867 Total revenue6,171 18,141 Operating expenses  Research and development54,037 73,700 General and administrative22,108 22,475 Change in fair value of contingent consideration2,625 69 Restructuring costs3,720 — Total operating expenses82,490 96,244 Loss from operations(76,319)(78,103)Other income  Interest income6,585 5,688 Interest expense(137)(459)Foreign exchange (loss) / gain(49)25 Total other income6,399 5,254 Loss before income taxes(69,920)(72,849)Income tax expense— — Net loss$(69,920)$(72,849)Loss per share  Basic and diluted$(0.38)$(0.44)Weighted average number of common shares  Basic and diluted185,608,874 165,960,379 Comprehensive loss  Unrealized gain on available-for-sale securities$286 $2,067 Comprehensive loss$(69,634)$(70,782)

See accompanying notes to the consolidated financial statements.

 78

ARBUTUS BIOPHARMA CORPORATION

Consolidated Statement of Stockholders’ Equity

(Expressed in thousands of US Dollars, except share and per share amounts)

Common Shares Number of sharesShare capitalAdditional paid-in capitalDeficitAccumulated other comprehensive lossTotal stockholders' equityBalance at December 31, 2022157,455,363 $1,318,737 $72,406 $(1,203,803)$(50,488)$136,852 Stock-based compensation— — 9,301 — — 9,301 Issuance of common shares pursuant to the Open Market Sales Agreement12,020,257 29,852 — — —